Company & Sponsor Intelligence
Amylyx Pharmaceuticals Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting1
Completed1
Countries2
Therapeutic footprint
als
Indexed studies
NCT06665165AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
als · United StatesPHASE1
als · United StatesPHASE1
NCT05619783Extension Study Evaluating The Safety And Tolerability of AMX0035
als · BelgiumPHASE3
als · BelgiumPHASE3
NCT05286372An Intermediate Size Expanded Access Protocol of AMX0035 for ALS
als · United StatesAPPROVED_FOR_MARKETING
als · United StatesAPPROVED_FOR_MARKETING
Intelligence layer updated: 2026-11-03 06:12:30.767591+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →